%0 Journal Article
%T GLP-1RA: New Hope in Obesity Therapy
%A Danfeng Zhang
%A Hongyun Lu
%J Journal of Biosciences and Medicines
%P 465-479
%@ 2327-509X
%D 2025
%I Scientific Research Publishing
%R 10.4236/jbm.2025.132035
%X Obesity has become a global chronic metabolic disease, posing a serious threat to public health. Glucagon-like peptide-1 (GLP-1) is an important hormone secreted by the L cells of the small intestine during food digestion. It plays a key role in maintaining glucose homeostasis, by promoting insulin synthesis and secretion, inhibiting glucagon release, and reducing hepatic glycogen output. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are analogs of GLP-1 that can resist degradation by DPP4 enzyme. They exert multiple physiological effects by activating the glucagon-like peptide-1 receptor (GLP-1R) and its downstream signaling pathways, including enhancing insulin secretion, suppressing appetite, and slowing gastric emptying. As a new class of weight management drugs, GLP-1RAs have diverse weight loss mechanisms and significant clinical effects. The new GLP-1RA, which has better weight loss, better safety, and improved dosing methods, significantly improves patient compliance. This article systematically summarizes the mechanism of action, efficacy, and safety of GLP-1 receptor agonists in weight loss treatment, aiming to provide new insights and evidence for clinicians when selecting medications for weight reduction.
%K Glucagon-Like Peptide-1
%K Glucagon-Like Peptide-1 Receptor Agonists
%K Obesity
%K Clinical Application
%K Adverse Reactions
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=140824